Review Open access

Omics Biomarkers in Precision Oncology: From the Lens of the ASCPT Biomarkers and Translational Tools and Oncology Communities

Mai Mehanna H. Mody Joy C. Hsu J. Quintanilha Zachary L. Taylor Angela James Binita Rajbanshi Pooja Manchandani L. M. Chekka

Aug 2026 · Clinical and Translational Science · Vol 19 · 0 citations · 10 references

Medicine

TL;DR

The biomarkers discussed here span a wide evidentiary spectrum, from those endorsed in clinical guidelines to those that remain investigational.

Abstract

Omics biomarkers comprise several molecular entities, including genomic, epigenomic, transcriptomic, proteomic, and metabolomic signatures. They play an essential role in oncology drug development and clinical settings by enabling personalized medicine. In precision oncology, validating biomarkers is a greater challenge than discovering them. The biomarkers discussed here span a wide evidentiary spectrum, from those endorsed in clinical guidelines to those that remain investigational.

DOI PubMed Semantic Scholar

Read PDF

Similar papers

Review Open access Sep 2026

Multi-omics integration of proteomics and metabolomics in pediatric health and disease

Practical considerations for integrating proteomics and metabolomics in pediatric multi-omics research are discussed, including popular code- and web-based tools, and recent examples of multi-omics studies in pediatric cohorts, concluding with current challenges and future outlooks for integrative multi-omics studies.

Andrei M. Matusa, D. Tweddell, Mark J. Daley et al. · Communications Medicine · 0 citations

Editorial Open access Sep 2026

Special Issue ‘Molecular Mechanisms and New Markers of Cancer’—From Static Biomarkers to Context-Aware Precision Oncology

Cancer molecular medicine has been built on a compelling premise: if the alteration that sustains a tumor can be identified, it can be measured, interpreted, and eventually targeted [...].

A. d'Amati · International Journal of Mol... · 0 citations

Review Open access Sep 2026

Decoding the cancer microbiome: multi-omics, AI, and translational opportunities

The development, interpretation, and validation of AI models as key considerations for their integration and analysis are discussed, and practical suggestions for improving the reliability and biological relevance of AI-driven discoveries are provided.

Yu-Han Sun, Olivia J. Cheng, A. Ma et al. · Genome Biology · 0 citations

Editorial Open access Sep 2026

Special Issue “Molecular Biomarkers in Cancers: Advances and Challenges”

Cancer remains one of the most formidable challenges in contemporary medicine, due to not only its substantial and growing global burden but also the profound biological heterogeneity that characterizes individual tumors [...].

P. Tappia, B. Ramjiawan · International Journal of Mol... · 0 citations

Open access Sep 2026

A multi-stage prospective study evaluates serum metabolomic signatures for the differential diagnosis and prognostic stratification of PDAC

Highlights • Serum metabolomics identifies novel biomarkers for PDAC diagnosis and prognosis.• A specific 4-metabolite panel distinguishes PDAC from chronic pancreatitis.• Combining these four metabolites with CA19-9 achieves a diagnostic AUC of 0.999.• The metabolic signature offers prognostic value independent of cli...

Z. Ning, Ying Zhu, Hui Li et al. · Translational Oncology · 1 citation

Open access Sep 2026

Multi‐Omics Integration Identifies a Five‐Gene Metabolic Signature With Experimental Validation in Clear Cell Renal Cell Carcinoma

This study aims to systematically decipher the metabolic‐immune interplay in ccRCC through multi‐omics integration, with the goal of identifying robust prognostic biomarkers and actionable therapeutic vulnerabilities.

Yi Peng, S. Qin, Xi-Wen Li et al. · Cancer Reports · 0 citations